PURPOSE: To compare our standard technique for postprostatectomy radiotherapy of prostate cancer, i.e. using two lateral conformal dynamic arcs with volumetric-modulated arc therapy (VMAT) performed with the RapidArc(®) (Varian Medical Systems, Palo Alto, CA, USA). The plans were referred to as DA and RA, respectively. MATERIALS AND METHODS: The treatment plans of 44 patients receiving adjuvant/salvage radiotherapy in the first months of 2010 were compared. In all cases, the prescribed total dose was 66-68.2 Gy (2.2 Gy per fraction). Both DA and RA plans were optimized in terms of dose coverage and constraints. RESULTS: Small differences between the techniques were observed for planning target volume (PTV) dose distribution, whereas significant differences in sparing of organs at risk (OARs) were recorded (p < 0.0001). The OAR values (median; 95 % confidence interval, CI) were: rectum: D30 % = 60.7 Gy (59.40-62.04 Gy) and 48.2 Gy (46.40-52.72 Gy), D60 % = 34.1 Gy (28.50-38.92 Gy) and 27.7 Gy (21.80-31.51 Gy); bladder: D30 % = 57.3 Gy (45.83-64.53 Gy) and 46.4 Gy (33.23-61.48 Gy), D50 % = 16.4 Gy (11.89-42.38 Gy) and 17.2 Gy (10.97-27.90 Gy), for DA and RA, respectively. Treatment times were very similar, whereas the monitor units (MU) were 550 ± 29 versus 277 ± 3 for RA and DA, respectively. CONCLUSION: Dose-volume histograms (DVHs) show improvements in OAR sparing with RA. However, the RA technique is associated with almost double the number of MUs compared to DA. Regarding the PTV, DA is slightly superior in terms of D2 % and dose homogeneity. On the whole, the results suggest that RA be the favorable technique.
PURPOSE: To compare our standard technique for postprostatectomy radiotherapy of prostate cancer, i.e. using two lateral conformal dynamic arcs with volumetric-modulated arc therapy (VMAT) performed with the RapidArc(®) (Varian Medical Systems, Palo Alto, CA, USA). The plans were referred to as DA and RA, respectively. MATERIALS AND METHODS: The treatment plans of 44 patients receiving adjuvant/salvage radiotherapy in the first months of 2010 were compared. In all cases, the prescribed total dose was 66-68.2 Gy (2.2 Gy per fraction). Both DA and RA plans were optimized in terms of dose coverage and constraints. RESULTS: Small differences between the techniques were observed for planning target volume (PTV) dose distribution, whereas significant differences in sparing of organs at risk (OARs) were recorded (p < 0.0001). The OAR values (median; 95 % confidence interval, CI) were: rectum: D30 % = 60.7 Gy (59.40-62.04 Gy) and 48.2 Gy (46.40-52.72 Gy), D60 % = 34.1 Gy (28.50-38.92 Gy) and 27.7 Gy (21.80-31.51 Gy); bladder: D30 % = 57.3 Gy (45.83-64.53 Gy) and 46.4 Gy (33.23-61.48 Gy), D50 % = 16.4 Gy (11.89-42.38 Gy) and 17.2 Gy (10.97-27.90 Gy), for DA and RA, respectively. Treatment times were very similar, whereas the monitor units (MU) were 550 ± 29 versus 277 ± 3 for RA and DA, respectively. CONCLUSION: Dose-volume histograms (DVHs) show improvements in OAR sparing with RA. However, the RA technique is associated with almost double the number of MUs compared to DA. Regarding the PTV, DA is slightly superior in terms of D2 % and dose homogeneity. On the whole, the results suggest that RA be the favorable technique.
Authors: Akila N Viswanathan; Ellen D Yorke; Lawrence B Marks; Patricia J Eifel; William U Shipley Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-01 Impact factor: 7.038
Authors: Piet Ost; Bart De Troyer; Valérie Fonteyne; Willem Oosterlinck; Gert De Meerleer Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-01 Impact factor: 7.038
Authors: Shawn Malone; Jennifer Croke; Nicolas Roustan-Delatour; Eric Belanger; Leonard Avruch; Colin Malone; Christopher Morash; Cathleen Kayser; Kathryn Underhill; Yan Li; Kyle Malone; Balazs Nyiri; Johanna Spaans Journal: Int J Radiat Oncol Biol Phys Date: 2012-03-22 Impact factor: 7.038
Authors: F Alongi; A Fogliata; P Navarria; A Tozzi; P Mancosu; F Lobefalo; G Reggiori; A Clivio; L Cozzi; M Scorsetti Journal: Strahlenther Onkol Date: 2012-09-29 Impact factor: 3.621
Authors: T Rancati; C Fiorino; G Gagliardi; G M Cattaneo; G Sanguineti; V Casanova Borca; C Cozzarini; G Fellin; F Foppiano; G Girelli; L Menegotti; A Piazzolla; V Vavassori; R Valdagni Journal: Radiother Oncol Date: 2004-10 Impact factor: 6.280
Authors: D Zerini; B A Jereczek-Fossa; C Fodor; F Bazzani; A Maucieri; S Ronchi; S Ferrario; S P Colangione; M A Gerardi; M Caputo; A Cecconi; F Gherardi; A Vavassori; S Comi; R Cambria; C Garibaldi; F Cattani; O De Cobelli; R Orecchia Journal: Br J Radiol Date: 2015-06-09 Impact factor: 3.039
Authors: B A Jereczek-Fossa; A Maucieri; G Marvaso; S Gandini; C Fodor; D Zerini; G Riva; O Alessandro; A Surgo; S Volpe; G Fanetti; S Arculeo; M A Zerella; S Parisi; P Maisonneuve; A Vavassori; F Cattani; R Cambria; C Garibaldi; A Starzyńska; G Musi; O De Cobelli; M Ferro; F Nolè; D Ciardo; R Orecchia Journal: Med Oncol Date: 2018-11-27 Impact factor: 3.064
Authors: Hanne Elisabeth Weber; Leif Hendrik Dröge; Steffen Hennies; Markus Karl Herrmann; Jochen Gaedcke; Hendrik Andreas Wolff Journal: Strahlenther Onkol Date: 2015-06-08 Impact factor: 3.621